Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based derivative molecule, completing the company’s broad series of PCT applications covering this family of compounds.
The Naples-based biotech company's robust tryptamine-derivative intellectual property portfolio claims novel molecules structurally related to certain naturally occurring psychedelics, such as dimethyltryptamine (DMT), psilocybin, psilocin, and 5-MeO-DMT.
Some of the naturally occurring molecules are themselves currently being investigated by researchers around the world as potential treatments for a broad range of psychiatric and neurologic disorders including depression, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, eating disorders, pain, autism, and Alzheimer’s disease.
READ: Enveric Biosciences collaborates with University of Calgary to establish clinical trial for EVM-101 in cancer related distress
"With the aim of optimizing commercial and regulatory success, a primary focus of Enveric is the creation of novel molecules with improved pharmaceutical characteristics that are also protected by composition of matter, manufacturing, and method-of-use patent claims," said Peter Facchini, chief innovation officer, Enveric.
Enveric's extensive intellectual property portfolio enables the company to invest in, and harness, the therapeutic potential of these molecules, he noted.
“In our pursuit to maximize the potential of our large and diverse library of novel and protected drug candidates, we intend to pursue out-licensing opportunities to collaborate with other leading drug development companies with a similar focus on delivering benefits to patients suffering from psychiatric and neurologic disorders,” Facchini said.
Contact Ritika at ritika@proactiveinvestors.com